Akari Therapeutics Plc (NASDAQ: AKTX) announced preclinical data showing synergistic activity between its experimental cancer drug AKTX-101 and KRAS inhibition ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE